379 related articles for article (PubMed ID: 18047951)
1. Vaccine therapy for prostate cancer.
Sonpavde G; Spencer DM; Slawin KM
Urol Oncol; 2007; 25(6):451-9. PubMed ID: 18047951
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer immunotherapy.
McNeel DG
Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.
Simons JW; Sacks N
Urol Oncol; 2006; 24(5):419-24. PubMed ID: 16962494
[TBL] [Abstract][Full Text] [Related]
4. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutics in development for prostate cancer.
Harzstark AL; Small EJ
Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
[TBL] [Abstract][Full Text] [Related]
6. New molecular targets in advanced prostate cancer.
Dawson NA
Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072
[TBL] [Abstract][Full Text] [Related]
7. [Vaccine therapy of prostate cancer].
Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R
Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265
[TBL] [Abstract][Full Text] [Related]
9. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
10. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
11. Management of high risk metastatic prostate cancer: the case for novel therapies.
Brand TC; Tolcher AW
J Urol; 2006 Dec; 176(6 Pt 2):S76-80; discussion S81-2. PubMed ID: 17084174
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic vaccines for prostate cancer.
Cha E; Fong L
Curr Opin Mol Ther; 2010 Feb; 12(1):77-85. PubMed ID: 20140819
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in immunotherapy for the treatment of prostate cancer.
Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW
Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925
[TBL] [Abstract][Full Text] [Related]
14. Current status of experimental therapeutics for prostate cancer.
Moon C; Park JC; Chae YK; Yun JH; Kim S
Cancer Lett; 2008 Aug; 266(2):116-34. PubMed ID: 18440696
[TBL] [Abstract][Full Text] [Related]
15. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
Arlen PM; Gulley JL; Tsang KY; Schlom J
Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
[TBL] [Abstract][Full Text] [Related]
16. DNA vaccines for the treatment of prostate cancer.
Alam S; McNeel DG
Expert Rev Vaccines; 2010 Jul; 9(7):731-45. PubMed ID: 20624047
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for prostate cancer - recent progress in clinical trials.
Kipp RT; McNeel DG
Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
[TBL] [Abstract][Full Text] [Related]
18. Immunologic approaches to the treatment of prostate cancer.
Harris DT; Matyas GR; Gomella LG; Talor E; Winship MD; Spitler LE; Mastrangelo MJ
Semin Oncol; 1999 Aug; 26(4):439-47. PubMed ID: 10482186
[TBL] [Abstract][Full Text] [Related]
19. [State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus].
Eymard JC; Gervais A; Jarcau R; Bernard J
Bull Cancer; 2007 Jul; 94(7 Suppl):F69-76. PubMed ID: 17845996
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for prostate cancer.
Hrouda D; Perry M; Dalgleish AG
Semin Oncol; 1999 Aug; 26(4):455-71. PubMed ID: 10482188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
